Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month price targets for Kiniksa Pharmaceuticals' shares. Their KNSA share price forecasts range from $34.00 to $34.00. On average, they predict the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 160.7% from the stock's current price.
View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts.

Kiniksa Pharmaceuticals' stock was trading at $11.77 on January 1st, 2022. Since then, KNSA shares have increased by 10.8% and is now trading at $13.04.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our KNSA earnings forecast.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its quarterly earnings data on Monday, November, 1st. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.21. The firm earned $12.10 million during the quarter, compared to the consensus estimate of $9.92 million. Kiniksa Pharmaceuticals had a negative net margin of 124.52% and a negative trailing twelve-month return on equity of 62.36%.

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

(KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Kiniksa Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (1.18%), Walleye Capital LLC (0.43%), Integral Health Asset Management LLC (0.34%), Swiss National Bank (0.10%), Hennion & Walsh Asset Management Inc. (0.10%) and Personal CFO Solutions LLC (0.02%). Insiders that own company stock include John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends.

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KNSA stock can currently be purchased for approximately $13.04.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $903.36 million and generates $38.54 million in revenue each year. The company earns $-157,920,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

The company employs 215 workers across the globe.

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at 448081896257 or via email at ir@kiniksa.com.